Please cite this article as follows: Morita Y, Ujike H, Tanaka Y, Kishimoto M, Okahisa Y, Kotaka T, Harano M, Inada T, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2007. The Glycine Transporter 1 Gene (GLYT1) is Associated With Methamphetamine-Use Disorder. Am J Med Genet Part B 147B:54–58.
The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder†
Article first published online: 20 JUN 2007
Copyright © 2007 Wiley-Liss, Inc.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Volume 147B, Issue 1, pages 54–58, 5 January 2008
How to Cite
Morita, Y., Ujike, H., Tanaka, Y., Kishimoto, M., Okahisa, Y., Kotaka, T., Harano, M., Inada, T., Komiyama, T., Hori, T., Yamada, M., Sekine, Y., Iwata, N., Iyo, M., Sora, I., Ozaki, N. and Kuroda, S. (2008), The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am. J. Med. Genet., 147B: 54–58. doi: 10.1002/ajmg.b.30565
- Issue published online: 14 DEC 2007
- Article first published online: 20 JUN 2007
- Manuscript Accepted: 13 APR 2007
- Manuscript Received: 9 NOV 2006
- Zikei Institute of Psychiatry (Okayama, Japan)
- Ministry of Health, Labour and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- substance dependence;
- glycine transporter (GlyT);
- association study
Glycine transporter (GlyT)-1 plays a pivotal role in maintaining the glycine level at the glutamatergic synapse. Glycine is an allosteric agonist of N-methyl-D-aspartate (NMDA) receptors. Because activation of NMDA receptors is an essential step for induction of methamphetamine dependence and psychosis, differences in the functioning of GlyT-1 due to genetic variants of the GlyT-1 gene (GLYT1) may influence susceptibility. A case-control genetic association study of the GLYT1 gene examined 204 patients with methamphetamine-use disorder and 210 healthy controls. We examined three single nucleotide polymorphisms (SNPs), SNP1, IVS3 + 411C > T, rs2486001; SNP2, 1056G > A, rs2248829; and SNP3, IVS11 + 22G > A, rs2248632, of the GLYT1 gene and found that SNP1 showed a significant association in both genotype (P = 0.0086) and allele (P = 0.0019) with methamphetamine-use disorder. The T-G haplotype at SNP1 and SNP2 was a significant risk factor for the disorder (P = 0.000039, odds ratio: 2.04). The present findings indicate that genetic variation of the GLYT1 gene may contribute to individual vulnerability to methamphetamine dependence and psychosis. © 2007 Wiley-Liss, Inc.